Analyzing QGEN Stock Performance – A Market Overview

By Tamara Parker • Wednesday, October 21 10:46 • Permanent Link

Qiagen logged a -1.5% change during today's morning session, and is now trading at a price of $48.15 per share. The S&P 500 index moved 0.0%. QGEN's trading volume is 2,523,931 compared to the stock's average volume of 2,586,128.

Qiagen trades -0.1% away from its average analyst target price of $48.2 per share. The 15 analysts following the stock have set target prices ranging from $40.0 to $55.0, and on average have given Qiagen a rating of buy.

If you are considering an investment in QGEN, you'll want to know the following:

Qiagen's current price is 75.4% above its Graham number of $27.45, which implies that at its current valuation it does not offer a margin of safety
Qiagen has moved 0.6% over the last year, and the S&P 500 logged a change of 15.1%
Based on its trailing earnings per share of 1.97, Qiagen has a trailing 12 month Price to Earnings (P/E) ratio of 24.4 while the S&P 500 average is None
QGEN has a forward P/E ratio of 18.4 based on its forward 12 month price to earnings (EPS) of $2.61 per share
The company has a price to earnings growth (PEG) ratio of 1.23 — a number near or below 1 signifying that Qiagen is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.96 compared to its sector average of None
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Based in Venlo, the company has 5,500 full time employees and a market cap of $9.94 Billion. Qiagen currently returns an annual dividend yield of 0.7%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.